Product Description
Pramipexole is a medication used in the management and treatment of Parkinsonism and restless leg syndrome. It is in the anti-parkinsonian class of drugs. (Sourced from: https://www.ncbi.nlm.nih.gov/books/NBK557539/)
Mechanisms of Action: D2 Agonist,D3 Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: Parkinson Disease | Restless Legs Syndrome
Known Adverse Events: Hypotension | Hypotension, Orthostatic | Amnesia | Confusion | Dizziness | Dystonia | Hallucinations | Headache | Insomnia | Mouth Abnormalities | Skin Abnormalities | Asthenia | Constipation
Company: Boehringer Ingelheim
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Botswana, Brazil, Germany, India, Kenya, Malawi, Mexico, Peru, Philippines, Portugal, South Africa, Thailand, Uganda, United States, Vietnam, Zimbabwe
Active Clinical Trial Count: 4
Highest Development Phases
Phase 2: Cognitive Dysfunction|Depressive Disorder, Major|Obsessive-Compulsive Disorder
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| OCD-RT | P2 |
Unknown Status |
Obsessive-Compulsive Disorder |
2028-12-31 |
|
| A5402 | P2 |
Not yet recruiting |
Depressive Disorder, Major|Cognitive Dysfunction |
2026-12-02 |
|
| CTC-003 | P2 |
Active, not recruiting |
Depressive Disorder, Major |
2025-12-30 |
|
| U1111-1303-3852 | P1 |
Completed |
Healthy Volunteers |
2024-08-12 |